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Abstract
Background:  GSAO (4-[N-[S-glutathionylacetyl]amino] phenylarsenoxide) is a hydrophilic
derivative of the protein tyrosine phosphatase inhibitor phenylarsine oxide (PAO). It inhibits
angiogenesis and tumour growth in mouse models and may be evaluated in a phase I clinical trial in
the near future. Initial experiments have implicated GSAO in perturbing mitochondrial function.
Other molecular effects of GSAO in human cells, for example on the phosphorylation of proteins,
are still largely unknown.
Methods: Peripheral white blood cells (PWBC) from healthy volunteers were isolated and used
to profile effects of GSAO vs. a control compound, GSCA. Changes in site-specific
phosphorylations, other protein modifications and expression levels of many signalling proteins
were analysed using more than 400 different antibodies in Western blots.
Results: PWBC were initially cultured in low serum conditions, with the aim to reduce basal
protein phosphorylation and to increase detection sensitivity. Under these conditions pleiotropic
intracellular signalling protein changes were induced by GSAO. Subsequently, PWBC were cultured
in 100% donor serum to reflect more closely in vivo conditions. This eliminated detectable GSAO
effects on most, but not all signalling proteins analysed. Activation of the MAP kinase Erk2 was still
observed and the paxillin homologue Hic-5 still displayed a major shift in protein mobility upon
GSAO-treatment. A GSAO induced change in Hic-5 mobility was also found in endothelial cells,
which are thought to be the primary target of GSAO in vivo.
Conclusion: Serum conditions greatly influence the molecular activity profile of GSAO in vitro.
Low serum culture, which is typically used in experiments analysing protein phosphorylation, is not
suitable to study GSAO activity in cells. The signalling proteins affected by GSAO under high serum
conditions are candidate surrogate markers for GSAO bioactivity in vivo and can be analysed in
future clinical trials. GSAO effects on Hic-5 in endothelial cells may point to a new intracellular
GSAO target.
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Background
The term 'cancer' encompasses a wide variety of distinct,
multigenic diseases. Even within a specific tumour type, a
remarkable degree of heterogeneity on the level of DNA
lesions and affected signalling pathways is apparent.
Many cancer relevant signalling molecules, but also many
molecular targets of anti-cancer drugs, therefore remain
unknown. Prominent examples of signalling protein
classes long known to be involved in generating cancer
pathologies include GTPases, protein kinases and tran-
scription factors. By contrast, protein phosphatases have
only recently entered the stage as known players in cancer
development. At least 30 protein phosphatases are now
implicated in cancer development and other human dis-
eases [1-3]. In some of these cases, mutational inactiva-
tion of a protein phosphatase appears to mimic the
constitutive activation of its target kinase(s) [3]. In other
cases, hyperactivation or deregulation of a phosphatase
may contribute to kinase activation. For example, overex-
pression of the Cdc25 family phosphatases, which control
cell cycle progression, is well documented for a variety of
cancers, making the Cdc25 proteins interesting potential
targets for anti-cancer therapies [4-7] and references
therein).
The modulation of specific cellular signalling pathways to
treat human cancers has only recently developed into an
area of intense clinical research activity. A large number of
clinical trials for novel signal transduction modulator
(STM) drugs are currently planned or under way. STM
drugs often have relatively low toxicity, so determination
of the maximum tolerated dose (MTD) may not be a
prime goal for phase I clinical trials. Instead, identifica-
tion of an optimal biologically active dose (OBD) is essen-
tial [8]. Rapid determination of the OBD requires that in
vivo markers of drug activity are available before or very
early during the clinical trial.
This study identifies several proteins in PWBC which are
affected by the novel anti-cancer compound GSAO (4-[N-
[S-glutathionylacetyl]amino] phenylarsenoxide) [9] (Fig-
ure 1A). They may be useful as clinical surrogate markers
to monitor or predict the anti-cancer activity of GSAO and
could also help to provide further insight into the biolog-
ical mechanisms of GSAO action.
GSAO has anti-angiogenic activity in vitro and in vivo [10].
Mitochondria and in particular the adenine nucleotide
translocator (ANT) have been described as one target of
GSAO. However, mitochondria are present in virtually all
living cells. Therefore, inhibition of ANT does not per se
explain the low toxicity and anti-angiogenic activity of
GSAO.
Recent studies have revealed that differences in multidrug
resistance proteins (MRP1 and 2) and cellular glutathione
levels [11] appear to contribute to the preferential in vivo
activity of GSAO in endothelial cells. Nevertheless, it is
well known that practically all drugs in clinical use have
multiple molecular in vivo targets. They depend on the
affected cell type and applied doses. Some of these targets
are intimately linked to the adverse effects of the drug. In
cancer cells, with their heterogeneous genetic lesions,
drug targets can even be present in different combinations
or at different expression and activity levels when compar-
ing individual patients. Identification and monitoring of
novel molecular targets could thus help to understand
why a drug is more effective or toxic in some patients com-
pared to others. PWBC from donated blood were chosen
for the analyses, since they are easily obtainable from
healthy volunteers prior to clinical trial and later from the
patients enrolled in the trials. A main focus of the experi-
ments was to detect changes in protein phosphorylation
induced by GSAO treatment, because GSAO is a
hydrophilic derivative of phenylarsine oxide (PAO), a
well known protein phosphatase inhibitor [12,13]. In
contrast to GSAO, PAO is unsuitable for in vivo applica-
Chemical structure GSAO and GSCA and Dose-dependent  increase of PWBC protein tyrosine phosphorylation induced  by GSAO Figure 1
Chemical structure GSAO and GSCA and Dose-
dependent increase of PWBC protein tyrosine phos-
phorylation induced by GSAO. A and B. The boxes indi-
cate the region of the molecule thought to be primarily 
responsible for the biological activity of GSAO and the cor-
responding region in the control GSCA. Oxidation of GSAO 
is possible. The resulting molecule (GSAA) is thought to be 
inactive, but may become active again, if reduced in vivo. To 
avoid oxidation, GSAO solutions are prepared freshly, or 
stored after snap-freezing at -80°C. No significant activity 
loss of deep-frozen GSAO was observed for up to 6 months. 
PWBC were treated with GSAO or GSCA where indicated 
for 24 h and tyrosine phosphorylation detected by western 
blot. C 50 μM GSCA does not alter the protein pTyr levels 
of PBWC detectably. D Changes in protein pTyr patterns 
are apparent with as little as 1.5 μM GSAO. GSAO-affected 
proteins are indicated with arrows.
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tions and toxic for cells at nanomolar concentrations [10].
It penetrates very rapidly into cell membranes and is
hence not equally distributed throughout the vascular sys-
tem of an organism. As GSAO is expected to enter a phase
I clinical trial in the near future a molecular profiling of its
effects on signalling proteins prior to the trial was per-
formed. The aim was to provide data for trial-supporting
pharmacodynamic molecular assays, trial design and pos-
sibly identification of additional mechanisms of GSAO
action.
Methods
Isolation and culture of PWBC from healthy human 
volunteers
PWBC were obtained from 14 healthy volunteers not tak-
ing any medication (8 male, 6 female; aged between 23
and 60 years) with informed consent. Ethical approval
was granted by the Oxfordshire Ethics Committee (study
number 05/Q1605/59). Cell preparations from more
than 40 different blood donations were used. All blood
donations took place between 9 and 11 a.m. to minimise
potential circadian changes of signalling proteins. Whole
blood (54 ml) was collected from a peripheral arm vein
into 6 ml of 46.7% (v/v) trisodium citrate (final concen-
tration 4.67%) and syringes immediately placed on a
nutator at room temperature for at least 5 min to ensure
complete mixing. Batches of 20 ml citrated blood were
then carefully layered onto 20 ml Polymorphprep™ den-
sity gradient media (Axis Shield PoC AS, Oslo, Norway)
and centrifuged at 500 × g for 30 min at 20°C to remove
erythrocytes. PWBC were collected from the medium/
serum interface, transferred into a 50 ml centrifuge tube
and gently resuspended in sterile PBS. PWBC were then
centrifuged for 20 min at 600 × g at 20°C, PBS was aspi-
rated and the PWBC pellet stored in ice. PWBC were sub-
sequently cultured in either 100% donor serum or
RPMI1640 supplemented with 0.5% foetal bovine serum
(FBS), 100 μg/ml penicillin-streptomycin and 2 mM L-
glutamate. Donor serum was simultaneously prepared
freshly from peripheral blood. For this, blood was col-
lected without anticoagulant and centrifuged for 30 min
at 3700 × g at 20°C. The supernatant was transferred into
a fresh centrifuge tube and incubated for 2 h at room tem-
perature with nutation to allow coagulation, before cen-
trifugation at 3700 × g for 30 min at 20°C to obtain
serum. Pelleted PWBC were resuspended in either growth
medium or donor serum and equilibrated for 2 h at 37°C
in a humidified cell culture incubator with 5% CO2,
before treatment with the compound of interest. Cells
were treated with either GSAO, the active drug, or 4-N-(S-
glutathionyl acetyl) amino) benzoic acid (GSCA) in
which the trivalent arsenic of GSAO has been replaced by
a carboxylic acid, as a control, for the concentrations and
durations indicated. Stock solutions of both GSCA and
GSAO were made at a concentration of 3 mM in RPMI
1640 and, since GSAO is prone to oxidation, stored in
aliquots at -80°C unless used immediately. PAO was
freshly dissolved in cell culture grade DMSO at a concen-
tration of 10 mM and diluted to 1 μM with medium.
Preparation and analyses of protein lysates
Treated or mock-incubated PWBC were scraped from tis-
sue culture flasks, transferred to a 50 ml centrifuge tube
filled with PBS and centrifuged at 3700 × g for 20 min at
20°C to pellet the cells. The PBS was completely aspirated
from the PWBC pellet and the pellet lysed directly in boil-
ing SDS-PAGE sample buffer (70 mM TrisHCl pH6.8, 5%
(v/v)  β-mercaptoethanol, 40% (v/v) glycerol, 3%(w/v)
SDS, 0.05% (w/v) bromophenol blue). The samples were
then boiled for a further 5 min, cooled to room tempera-
ture and sonicated for 30 seconds to fragment DNA con-
tained in the cell lysate. Proteins in the lysate were
resolved by SDS polyacrylamide gel electrophoresis (SDS-
PAGE) and electrotransferred to PVDF membranes
(Hybond P, Amersham Biosciences). The membranes
were blocked and probed overnight at 4°C with different
phospho-epitope specific or other antibodies according to
the antibody manufacturers instructions. Bound primary
antibodies were detected using horseradish peroxidase-
conjugated anti-mouse or anti-rabbit immunoglobulins
(Jackson ImmunoResearch Inc.) and ECL (Amersham
Biosciences). Equal loading of different protein extract
samples was routinely confirmed by Coomassie-blue
staining of an SDS-PAGE-separated aliquot prior to blot
analyses. Antibodies used in this study are compiled in the
additional files 8 and 9. The BD PowerBlot Western Array
Screen Service (BD Biosciences) was utilised to analyse
expression levels of 240 individually selected signalling
proteins using monoclonal antibodies.
Culture and treatment of HUVEC
Human umbilical vein endothelial cells (HUVEC) were
purchased from TCS Cell Works, (Botolph Claydon, UK)
and cultured according to the manufacturers conditions
with recommended growth media, cell attachment factor
and passage conditions. Cells were cultured in 10 cm
plates until 80% confluent before treatment with GSAO
or GSCA in growth media with high serum (15% FBS) for
24 hours at 37°C with 5% CO2. Cells were lysed with
boiling sample buffer. Protein analysis, SDS PAGE and
Western blots were carried out as described for the PWBC.
Results
Pleiotropic effects of GSAO on PWBC cultured in low 
serum conditions
In initial experiments it was determined how rapidly pro-
tein phosphorylation changes were detectable upon
GSAO treatment of freshly isolated PWBC from healthy
donors under low serum culture conditions. For this,
PWBC were incubated with GSAO or its more hydropho-BMC Cancer 2006, 6:155 http://www.biomedcentral.com/1471-2407/6/155
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bic relative PAO. As previously reported in the literature
for various cell types, increased tyrosine phosphorylation
was rapidly observed with PAO. Incubation of PWBC with
1 μM PAO for 1 h resulted in a hyper-phosphorylation of
protein-tyrosyl residues that was comparable to an incu-
bation of PWBC with 50 μM GSAO for 8 h (additional file
1). This was not unexpected, since GSAO is specifically
modified to greatly slow down its uptake into cells. Incu-
bation of PWBC with a single dose of GSAO for 24 h
instead of 8 h greatly enhanced the hyperphosphorylation
of proteins on tyrosine residues (figure 1C). Treatment
with 50 μM of the control compound GSCA (see figure 1B
for structure), which lacks the crucial arsenic moiety, did
not detectably affect basal PWBC protein-tyrosyl phos-
phorylation (figure 1C). Subsequently, titration experi-
ments showed that incubation of PWBC for 24 h with 1.5
μM GSAO readily induced hyper-phosphorylation (figure
1D). Similar results were obtained for threonine phos-
phorylation of proteins upon GSAO treatment of PWBC
(additional file 2). Nine different commercial anti-pSer
antibodies were also tested, but all were found not to be
suitable for our purposes (listed in additional file 9; data
not shown).
In a subsequent set of experiments, the effects of GSAO vs.
GSCA on specific signalling proteins in PWBC were inves-
tigated. The results are described and shown in additional
text file and additional files 1 to 11.
From this large data set we conclude that GSAO has rather
pleiotropic effects on the cell signalling protein network
of PWBC cultured in low serum conditions. Since it is very
unlikely that a drug which affects numerous key signalling
proteins would show the low toxicity profile seen in vivo
[10], we modified the PWBC culture system.
GSAO affects only a small subset of signalling proteins 
when PWBC are cultured in high serum
Figure 2 shows a comparison of GSAO-induced effects on
protein tyrosine phosphorylation of PWBC cultured in
low serum (0.5% FBS) versus 100% of donor serum. Cul-
ture of PWBC in 100% donor serum reduces the overall
level of tyrosine phosphorylation in non-treated and
GSCA-treated cells. It also reduces the intensity of changes
seen upon GSAO-treatment. Titration of GSAO showed
that, in the presence of 100% donor serum, increased
PWBC tyrosine phosphorylation is clearly observable with
15 μM GSAO treatment of PWBC for 24 h (figure 2B).
Subsequent analyses focussed on GSAO effects on high
serum-cultured PWBC with those phospho-epitope-spe-
cific antibodies, which had shown phosphorylation
changes under low serum culture conditions. From these
experiments, it is obvious that GSAO is affecting only a
much smaller number of proteins in high serum culture.
For example, p90Rsk phosphorylation on Ser380 and
phosphorylation of JNKs is at best barely observable in
high serum culture (figure 3C and 3D; compare to addi-
tional files 3 and 5). However, phosphorylation of Erk2
on Thr202/Tyr204 is obvious after exposure of cells to 50
μM GSAO for 24 h (figure 3A). Because the trial will
involve infusions of GSAO, more chronic exposure was
studied. Extension of the GSAO exposure time on PWBC
in high serum culture showed that 15 μM GSAO induces
Erk2 activation after 48 h and after 72 h a massive activa-
tion of Erk2 is seen (figure 3B).
The paxillin homologue Hic-5 (hydrogen oxide inducible
clone-5; [14] was one of the few other proteins which was
clearly affected by GSAO under high serum culture condi-
tions (figure 4). GSAO treatment induces a massive
mobility shift of the Hic-5 band at a concentration of 15
μM compound. This upshift is probably a consequence of
an altered phosphorylation state of Hic-5, however, other
modifications of Hic-5 upon GSAO treatment of PWBC
cannot be excluded. Phosphorylation of Hic-5 on Tyr38
and 60 has been previously reported [15,16], but phos-
pho-specific antibodies for these epitopes are unavailable.
A slight shift in Hic-5 mobility was occasionally seen with
as little as 5 μM GSAO (figure 4B).
Effects of GSAO on protein tyrosine phosphorylation are  also visible under high serum culture conditions Figure 2
Effects of GSAO on protein tyrosine phosphorylation 
are also visible under high serum culture conditions. 
A PWBC were cultured in low serum (0.5% FBS) or 100% 
donor serum and treated with 50 μM GSAO or GSCA for 24 
h where indicated. Overall, levels of protein tyrosine phos-
phorylation are lower in donor serum-cultured PWBC and 
the hyperphosphorylation of tyrosyl residues observed upon 
GSAO-treatment is less pronounced but still detectable. B 
GSAO dose-response of PWBC cultured in 100% donor 
serum. PWBC were treated for 24 h. GSAO-induced hyper-
phosphorylation on tyrosyl residues is clearly visible with 15 
μM GSAO.
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A third protein clearly affected by GSAO in high serum
PWBC culture was a PRK1/PKNα antibody-immunoreac-
tive band of 100 kDa (figure 5). Protein kinase C-related
kinases (PRKs, also designated PKNs) are known effectors
of Rho GTPases and activated by fatty acids and lipids in
vitro [17]. Phosphorylation of PRK1/PKNα Thr778 (cor-
responding to PRK2/PKNγ Thr816) in the activation loop
of the kinase leads to an increased catalytic activity of
PRKs/PKNs. While PRK1/PKNα and PRK2/PKNγ are ca.
120 and 140 kDa in size, respectively, PKNβ has an appar-
ent molecular weight of ca. 100 kDa. We were so far una-
ble to determine whether the observed band is indeed
PKNβ, due to a lack of suitable specific reagents.
In summary, the screen with a large number of epitope-
specific antibodies has resulted in the detection of three
candidate surrogate markers for GSAO activity in PWBC
under high serum conditions. To search for further poten-
tial markers, antibodies targeted against phosphorylated
substrate epitopes or docking motifs of a specific kinase or
kinase family were used on GSAO-, GSCA- or mock-
treated PWBC lysates.
Detection of further proteins affected by GSAO in PWBC 
high serum culture using kinase substrate-specific 
antibodies
Phosphorylated substrate epitope-directed antibodies for
the protein targets of the kinase families Akt, ATM/ATR,
Cdk, MAPK, PKA, PKC and PKD, as well as a PDK-1 phos-
pho-docking motif antibody (for details see additional
file 9) were used to detect changes in kinase substrate pro-
teins of PWBC cultured in high or low serum in the pres-
ence or absence of GSAO and GSCA. Selected results are
shown in figures 6 and additional files 6 and 7. GSAO-
induced protein phosphorylation changes were again, as
expected, much more pronounced under low serum cul-
ture conditions and served as a useful control for the gen-
eral functionality of the antibodies. GSAO-effects in high
serum-cultured PWBC were observed with the Akt (figure
6), PKA (additional file 6) and PKD (additional file 7)
GSAO effects Erk, but not p90Rsk or Jnk phosphorylation in PWBC high serum culture Figure 3
GSAO effects Erk, but not p90Rsk or Jnk phosphorylation in PWBC high serum culture. PWBC were cultured in 
100% donor serum and treated with GSAO or GSCA for 24 h as indicated.A Phosphorylation of Erk2 on the Thr202/Tyr204 
epitope is visible at 50 μM GSAO (upper panel). Total Erk protein levels remain unchanged after GSAO treatment for 24 h 
(lower panel). B Phosphorylation of Ser380 on p90Rsk is marginally increased at best in high serum cultured PWBC. C Phos-
phorylation of the Thr183/Tyr185 epitope on Jnks is marginally increased at best in high serum cultured PWBC.
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substrate-directed antibodies. These results show that a
range of further proteins affected by GSAO-exposure of
PWBC cultured in high serum remain to be identified.
GSAO affects signalling proteins in HUVEC endothelial 
cells
GSAO targets proliferating endothelial cells in vivo [10],
therefore experiments were carried out with primary
endothelial cells. Human umbilical vein endothelial cells
(HUVEC) were treated with 15 or 50 μM GSAO. Increased
tyrosine phosphorylation was observed in the HUVEC
upon 15 μM treatment with GSAO (figure 7A). The PRK1/
PKNα Thr778 antibody-immunoreactive band of 100
kDa was not detectable in HUVEC upon treatment with
GSAO and no changes in phosphorylation or protein
expression of PRK1/PKNα were detectable (figure 7B). No
induction of phosphorylation of Erk1/2 Thr202/Tyr204
was observed (figure 7B). However, GSAO treatment of
HUVEC with 50 μM GSAO clearly induces a mobility shift
of the Hic-5 band (see figure 7B) similar to that seen in
PWBC cultured in high serum.
Discussion
STM drugs are playing an increasingly important role in
cancer therapy. Many of these drugs appear to have low
toxicity profiles, so biological responses are expected
below drug concentrations, which lead to massive side
effects. Based on the results from previous animal studies
[10,18], one can speculate that this may also be the case
for novel anti-cancer compound GSAO. Surrogate mark-
ers that can be monitored to detect the biological activity
of a STM drug in patients shortly after drug application
may therefore be of great value for its optimal clinical
development.
GSAO induces phosphorylation of a 100 kDa protein which  is recognised by an antibody directed against PRK1/PKNα  pThr778 Figure 5
GSAO induces phosphorylation of a 100 kDa protein 
which is recognised by an antibody directed against 
PRK1/PKNα pThr778. PWBC were treated with GSCA 
or GSAO where indicated for 24 h and proteins analysed 
with anti-PRK1/PKNα pThr778. A Effect of 50 μM GSAOvs. 
GSCA on a 100 kDa protein recognised by anti-PRK1/PKNα 
pThr 778. A prominent hyperphosphorylation of the 100 
kDa protein is visible, while a signal of ca. 120 kDa, the size 
expected for PRK1/PKNα, remains unchanged. The 100 kDa 
band may correspond to the PRK1/PKNα relative PKNβ, but 
this can only be verified after the generation of PKNβ-spe-
cific antibodies. B GSAO dose – response in low serum cul-
tured PWBC. Hyperphosphorylation of the 100 kDa band is 
visible from 15 μM of GSAO with the pThr778-specific 
PRK1/PKNα antibody (upper panel) while total protein levels 
of PRK1/PKNα remain unchanged (lower panel). A mobility 
shift of PRK1/PKNα is also visible with this antibody at higher 
GSAO concentrations, possibly indicating a PRK1/PKNα 
phosphorylation at a site different from pThr778. C Effect of 
GSAO on the 100 kDa band in high serum cultured PWBC. 
A moderate increase of phosphorylation at the pThr778-
related epitope is visible at 50 μM GSAO.
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Prominent mobility change of Hic-5 in GSAO-treated PWBC  in low and high serum culture Figure 4
Prominent mobility change of Hic-5 in GSAO-
treated PWBC in low and high serum culture. Cells 
were treated with GSCA or GSAO as indicated for 24 h and 
analysed for Hic-5 expression and mobility. A Comparisonof 
effects induced by 15 μM GSAO under low and high serum-
culture conditions. In both cases a prominent band shift of 
Hic-5 isobserved. B GSAO dose – response of Hic-5 in 
PWBC culturedin 100% donor serum. A partial mobility shift 
is observable at 5 μM GSAO, but the band shift is more pro-
nounced at 15 μM GSAO.
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GSAO is thought to primarily interfere with proliferating
endothelial cells [10], hence disrupting the further growth
of tumour vasculature. GSAO activity is therefore depend-
ent on systemic distribution through the blood vessels
and capillaries but probably does not need to penetrate
deeply into tissues to exert key effects. As endothelial cells
and PWBC are both key components of the blood vessel
system and will be exposed to circulating GSAO to a sim-
ilar degree, PWBC should be well suited for the analysis of
surrogate markers for GSAO activity in vivo.
Our experiments clearly show that classical low serum cul-
ture, often used to reduce background signals prior to
addition of a drug or factor, is not ideal to find potential
markers for GSAO bioactivity in vivo. Furthermore, this
study was only possible through the multitude of com-
mercial signalling protein antibodies that have become
available in the last few years. These antibodies, directed
against specific phosphorylated or nonphosphorylated
protein epitopes in signalling proteins, allow the rapid
analysis of a significant part of the signalling phosphopro-
teome. In order to obtain reliable data with these antibod-
ies, their specificity must be carefully evaluated. In our
western blot experiments, we frequently found multiple
bands resulting from a single antibody analysed. Signals
appeared often at unexpected sizes, especially for polyclo-
nal anti sera. Until now, high quality monoclonal anti-
bodies are only available for a small number of
phosphoepitopes. We feel that this would make, at
present, results from high throughput (HTP) array-format
assays or FACS-based HTP analyses like multiplex-bead
assays difficult to properly evaluate.
Monitoring of drug effects on total protein expression lev-
els, is simpler, but appears to be overall less informative as
many phospho-changes are not mirrored by changes in
overall protein expression. Nevertheless, it can give some
initial leads and many good quality monoclonal antibod-
ies are readily available. For optimal retrieval of informa-
tion from western blot type assays it is necessary to
perform non-automated visual re-inspections to detect all
changes. The GSAO-induced Hic-5 mobility shift was
found through this approach and would have been
missed using a spot array or another technique not sepa-
rating proteins by apparent molecular weight.
Hic-5 is an interesting candidate for further analyses of
GSAO actions in cells. It is a member of the paxillin family
[19,20] and has been implicated in a variety of biological
processes including those that regulate cell motility, inva-
sion, survival and proliferation (summarised in [19]).
Effects of GSAO treatment on HUVEC Figure 7
Effects of GSAO treatment on HUVEC. HUVEC were-
incubated for 24 h with GSAO or GSCA as indicated with 
15% FBS. A Increased tyrosine phosphorylation is readily 
detectable at 15 μM GSAO treatment. Some GSAO affected 
proteins are indicated witharrows. B Hyperphosphorylation 
of the 100 kDa protein is undetectable in HUVEC, while a 
band of ca. 120 kDa, the size expected for PRK1/PKNα, 
remains unchanged. A band shift of Hic-5 is detectable at 50 
μM GSAO treatment. Phosphorylation changes in Erk2 at 
Thr202/Tyr204 are not detectable.
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Detection of proteins hyperphosphorylated after treatment  of PWBC with GSAO using an Akt substrate-directed anti- body Figure 6
Detection of proteins hyperphosphorylated after 
treatment of PWBC with GSAO using an Akt sub-
strate-directed antibody. Cells were incubated for 24 
hwith GSAO or GSCA as indicated and analysed with an 
antibody made to recognise multiple Akt substrate proteins 
in their Akt-phosphorylated forms (R/K-x-R/K-x-x-pS/pT 
motif, Cell Signalling Technology 9611). A Massive effect of 
GSAO on phosphoproteins detected with the Akt substrate 
phospho-antibody using protein extracts from low serum 
cultured PWBC. The control compound GSCA does not 
detectably change the basal phospho-protein pattern. B 
Effects of 15 μM GSAO on high serum culturedPWBC. 
Arrows indicate bands that are hyperphosphorylated inG-
SAO-treated cells.
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Moreover, recent publications have highlighted addi-
tional roles for Hic-5, for example, the suppression of Lef/
Tcf-driven transcription during vertebrate development
[21]. Hic-5 was also reported to undergo redox-sensitive
nuclear-cytoplasmic shuttling [22,23] and to interact with
Traf4, which is implicated in the oxidative regulation of
endothelial cell migration [24]. GSAO uptake and action
has also been shown to depend on redox parameters like
cellular glutathione levels [11], but it remains to be stud-
ied if GSAO directly influences theredox regulation of
cells or cellular subcompartments, for example by inter-
fering with redox-regulated phosphatases like PTP-PEST
[24] or other signalling proteins.
The consistent activation of the MAP kinase Erk2 by
GSAO under high and low serum conditions is also
intriguing, since no activation of its regulator kinases
MEK1/2 could be observed (data not shown). Apart from
a direct effect on Erk-inactivating phosphatases, like
MKPs, other more indirect changes in PWBC signalling
may lead to Erk2 activation. Since the intracellular GSAO
uptake is very slow and effects are usually seen after many
hours, a plethora of possible indirect mechanisms, includ-
ing changes in the transcription of certain genes may
underlie the observed Erk2 activity change. Erk2 activa-
tion is thought to trigger its dimerisation and nuclear
translocation [25], possibly leading to the phosphoryla-
tion of nuclear substrate proteins. Analyses of selected Erk
substrates like p90Rsk, and Elk-1 with phospho-epitope
specific antibodies (results summarised in additional file
9) did not pinpoint an affected Erk2 substrate so far and
an initial screen for substrates of proline-directed kinases
(like Erks and Cdks) with an antibody which recognises
an xxx-pThr-Pro-xxx motif did also not detect candidate
substrates in GSAO-treated PWBC culture in high serum
(not shown). Since more than 70 Erk substrates have been
reported so far, a large number of potential substrates
remain to be analysed. Beyond this, experiments with
substrate epitope-directed phospho-antibodies specific
for targets of other kinases clearly indicate that additional
GSAO-affected proteins, which could be useful bioactivity
markers, remain to be discovered.
Changes in one of the three candidate surrogate markers
for GSAO activity found in PWBC is detectable in
endothelial cells, but additional changes in tyrosine phos-
phorylation were observed in a multitude of proteins at
15 μM GSAO treatment in HUVEC. This suggests that
overlapping, but distinct groups of signalling pathways
are affected by GSAO in the different cell types. Further
studies into the biological mechanisms of GSAO interfer-
ence with endothelial cell proliferation are needed to elu-
cidate the in vivo activity of GSAO in this cell type.
Conclusion
This study has shown that GSAO effects on the PWBC
phosphoprotein signalling network are quite selective,
provided the appropriate experimental conditions are
used. The results also give suggestions for the develop-
ment of new reagents, which may be useful to support
future clinical studies and to possibly gain further insight
into the cellular targets of GSAO. Analyses with substrate
epitope-specific antibodies show that further GSAO-
affected proteins remain to be identified. Variation in
phosphorylation patterns between PWBC and HUVEC
suggest distinct pathway patterns become activated by
GSAO in different cell types. As PWBC are easily obtaina-
ble they are more probably suitable for measuring surro-
gate markers in future clinical studies, but endothelial
cells are clearly also an important cell type that needs to
be analysed further with molecular and functional assays.
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Additional material
Additional File 1
GSAO and phenylarsine oxide (PAO) induce similar patterns of tyro-
sine phosphorylation in peripheral white blood cells (PWBC). Freshly 
isolated PWBC were equilibrated in medium with 0.5% FBS for 2 h and 
then treated with the indicated concentrations of PAO or GSAO. PWBC 
were subsequently lysed and proteins analysed for protein tyrosine phos-
phorylation by western blot. Uptake of the hydrophilic GSAO into cells is, 
as expected, very slow. Treatment of PWBC with 50 μM GSAO for 8 h 
results in protein tyrosyl-hyperphosphorylation similar to that seen upon 
incubation with 1 μM PAO for 1 h. Hyperphosphorylated protein bands 
are indicated by arrows.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S1.PPT]BMC Cancer 2006, 6:155 http://www.biomedcentral.com/1471-2407/6/155
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Additional File 2
Dose-dependent increase of PWBC protein threonine phosphorylation 
induced by GSAO. PWBC were treated with GSAO or GSCA where indi-
cated for 24 h and threonine phosphorylation detected by western blot. A 
50 μM GSCA does not alter the protein pThr levels of PBWC detectably. 
B Changes in protein pThr patterns are apparent with as little as 1.5 μM 
GSAO. GSAO-affected proteins are indicated with arrows.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S2.PPT]
Additional File 3
GSAO induces phosphorylation of c-Jun N-terminal kinases (JNKs) at 
the kinase activity-regulating epitope (Thr 183/Tyr 185) in PWBC. 
PWBC were treated with GSAO or GSCA, then lysed and analysed by 
western blot for JNK expression or phosphorylation. The phospho-specific 
antibody detects JNK protein only effectively when doubly phosphorylated 
on Thr183 and Tyr185. A Cells were treated with 50 μM GSAO or GSCA 
for 24 h where indicated and analysed for phospho-JNK (upper panel) or 
total JNK (lower panel) B Cells were treated with different concentrations 
of GSAO for 24 h as indicated and analysed for phospho-JNK.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S3.ppt]
Additional File 4
Effects of GSAO on the MAP kinase cascade. Cells were treated with 
GSAO or GSCA as indicated for 24 h and lysates analysed for the phos-
phorylation of Erk1/Erk2 (pThr202/pTyr204) or c-Raf-1 (pTyr340/
pTyr341; pSer259). Phosphorylation of Erk1/Erk2 at the epitope Thr202/
Tyr204 correlates closely with Erk kinase activation. The phospho-epitopes 
analysed for c-Raf-1 also contribute to the regulation of c-Raf-1 kinase 
activity, but numerous other regulatory sites have been described in c-Raf-
1. A Effect of GSAO treatment on the phosphorylation of Erk1/Erk2 
(pThr202/pTyr204) detected by a polyclonal antibody (9101, Cell Sig-
nalling Technology). Apart from the major Erk1/2 phospho-bands, several 
additional phospho-bands of different sizes, some possibly representing 
other Erk family members, are visible. B Effect of GSAO treatment on the 
phosphorylation of Erk1/Erk2 (pThr 202/pTyr204) detected by a mono-
clonal antibody (M8159, Sigma). C Effect of GSAO treatment on the 
phosphorylation of c-Raf-1 at Tyr340/Tyr341. Phosphorylation of this 
epitope can contribute to the activation of Raf kinase. D Effect of GSAO 
treatment on the phosphorylation of c-Raf-1 at Ser259. Dephosphoryla-
tion of this epitope is thought to be important for activation of the kinase. 
The c-Raf-1 band shift observed with 15 and 50 μM GSAO, probably 
resulting from phosphorylation events at other c-Raf-1 epitopes, makes it 
difficult to determine if a partial dephosphorylation of pSer259 occurs at 
these GSAO concentrations.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S4.ppt]
Additional File 5
Effects of GSAO on the phosphorylation of p90Rsk at Ser380 in 
PWBC obtained from different volunteers. PWBC were treated with 
GSAO or GSCA as indicated for 24 h and lysates analysed for the phos-
phorylation of Ser380 in p90Rsk. Cells from three different donors were 
used. The male donor was analysed on two different occasions. Increased 
Ser380 phosphorylation is clearly visible at 5 μM GSAO in all cases. With 
50 μM GSAO a major mobility shift of p90Rsk (pSer380) is visible. This 
could indicate the occurrence of additional phosphorylation events.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S5.ppt]
Additional File 6
Detection of proteins hyperphosphorylated after treatment of PWBC 
with GSAO using a PKA substrate-directed antibody. Cells were incu-
bated for 24 h with GSAO or GSCA as indicated and analysed with an 
antibody made to recognise multiple PKA substrate proteins in their PKA-
phosphorylated forms (R-R-x-pS or R-x-x-pT motif, Cell Signalling Tech-
nology 9621). A Strong effect of GSAO on phosphoproteins detected with 
the PKC substrate phospho-antibody using protein extracts from low serum 
cultured PWBC. The control compound GSCA does not detectably change 
the basal phospho-protein pattern. B Effects of 15 μM GSAO on high 
serum cultured PWBC. Arrows indicate bands that are slightly hyperphos-
phorylated in GSAO-treated cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S6.ppt]
Additional File 7
Detection of proteins hyper-phosphorylated after treatment of PWBC 
with GSAO using a PKD substrate-directed antibody. Cells were incu-
bated for 24 h with GSAO or GSCA as indicated and analysed with an 
antibody made to recognise multiple PKD substrate proteins in their PKD-
phosphorylated forms (L-x-R-x-x-pT/pS motif, Cell Signalling Technology 
4381) A Effect of GSAO on phosphoproteins detected with the PKC sub-
strate phospho-antibody using protein extracts from low serum cultured 
PWBC. The control compound GSCA does not detectably change the basal 
phospho-protein pattern. B Effects of 15 μM GSAO on high serum cul-
tured PWBC. Arrows indicate three bands that are clearly hyperphospho-
rylated in GSAO-treated cells.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S7.ppt]
Additional File 8
Compiled results of the Powerblot™ comparison of PWBC cultured in 
low serum and treated with 50 μM GSAO or GSCA.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S8.xls]
Additional File 9
Antibodies used for analysis of GSAO effects on PWBC.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S9.xls]BMC Cancer 2006, 6:155 http://www.biomedcentral.com/1471-2407/6/155
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Additional File 10
Summary of GSAO-induced protein expression changes in PWBC cul-
tured with low serum medium. Of 240 individually selected signalling 
proteins, which were analysed by the commercially available Powerblot™, 
the 24 proteins listed here showed an apparent change in protein expres-
sion considered to be highly significant according to the company. Proteins 
in blue color are upregulated, proteins in black downregulated with GSAO 
vs. GSCA. From this list it is obvious, that kinases and PTPases and their 
targets make up the majority of proteins affected in their expression level 
by GSAO. At least two of the signals (LAT, VASP) are, however, clearly 
questionable, as the detected band size in the sample varies greatly from 
the expected protein size. In other cases, for example Hic-5, an expression 
change is detected by the automated system. Upon visual inspection this 
supposed expression change results from a mobility shift of Hic 5. A full 
list of all proteins analysed and changes detected are compiled in 3.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S10.ppt]
Additional File 11
Pleiotropic effects on PWBC in low serum conditions.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2407-6-155-S11.doc]